



Making a positive impact in society

At Ferrer we want to make a positive impact in society and we do so by reinvesting a significant part of our profits in initiatives with social and environmental impact, as well as in our people

In order to fulfil our purpose, we offer transformative therapeutic solutions, with an increasing focus on pulmonary vascular and interstitial lung diseases and neurological disorders, such as ALS



FERRER is the first Spanish pharmaceutical company to become part of the international B Corp community, the group of companies that aim to build a more inclusive and sustainable economy

We are Ferrer. Ferrer for good

MEET US AND LEARN MORE AT OUR VIRTUAL BOOTH

Major sponsor:



Save the date!



Join our expert panel session

CHECK YOUR TIME ZONE HERE



The challenges designing an ALS clinical trial for a timely drug approval and access

WED 7th DEC

17:05-17:50h GMT




INTRODUCTION & INTERACTIVE DISCUSSION



Leonard van den Berg

Department of Neurology at University Medical Center Utrecht and Chair of TRICALS, NDL.



WHAT'S THE BALANCE BETWEEN FUNCTION AND SURVIVAL ENDPOINTS AND ITS IMPACT IN TRIAL DESIGN?



Ruben van Eijk

University Medical Center Utrecht, NDL.



DOES A TRIAL POPULATION REPRESENT THE ALS POPULATION?



Adriano Chiò

Department of Neurology and Neurology Unit at the University of Torino and at Ospedale Città della Salute e della Scienza, Torino, IT.



BOOSTING pALS & cALS INVOLVEMENT IN CLINICAL TRIALS



Magdalena Kuzma-Kozakiewicz

Medical University of Warsaw, PL.



And do not miss our poster presentation

CHECK YOUR TIME ZONE HERE



To learn more about the ongoing phase 3 ADORE study with daily oral edaravone (FNP122) and the Open Label Extension study ADOREXT

Session B

WED 7th DEC

12:15-13:45h GMT

